If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf","IpdInfoTypeAnalyticCode":"false","IpdInfoTypeIcf":"false","IpdInfoTypeCsr":"false","IpdInfoTypeProtocol":"false","IpdInfoTypeSap":"false","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"No","acronym":"","allocation":"","arm_groups":[],"assignment":"","brief_summary":"This is a prospective observational cohort study. The primary aim is to observe the population receiving Cabotegravir (CAB) Long-acting (LA) for Pre-exposure prophylaxis (PrEP) in routine clinical practice, usage patterns, adherence, post marketing clinical effectiveness, discontinuations, and monitoring for resistance among individuals who receive an HIV diagnosis while on CAB LA for PrEP.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Cabotegravir Long-acting (CAB LA) pre-exposure prophylaxis (PrEP) Cohort: Prospective Cohort Study to Assess Adherence and Effectiveness of, and Monitor for Hepatotoxicity and Resistance to, Cabotegravir for Pre-Exposure Prophylaxis in Europe","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"04/04/2026 15:00:10","criteria":"Inclusion Criteria:\n\nHIV-negative adults and adolescents (at least 12 years of age) greater than or equal to (>=) 35 kilograms (kg) initiating CAB LA for PrEP will be eligible for inclusion from the date of starting OLI or CAB LA injections.\n\nExclusion Criteria: NA","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Planned","display_status_internal":"RECSTATUS_O_PLANNED","endpoint":"","enrollment":"","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"4c6c2541-6904-5285-a576-eb88312581fa","internal":{"content":null,"contentDigest":"de956c533627693c4439f463951c5fcd","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\n\nHIV-negative adults and adolescents (at least 12 years of age) greater than or equal to (>=) 35 kilograms (kg) initiating CAB LA for PrEP will be eligible for inclusion from the date of starting OLI or CAB LA injections.\n\nExclusion Criteria: NA","interventions":[],"interventional_subtype":"","is_fda_regulated":null,"is_high_value":false,"is_ind_study":null,"keywords":["Human Immunodeficiency Virus (HIV)","Cabotegravir","CAB LA","PrEP"],"last_follow_up_date":"12/30/2029 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"12","minimum_age_raw":"12 Years","modified_date":"04/04/2026 15:40:20","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"CAB LA PrEP Cohort: Prospective Cohort Study to Assess Adherence and Effectiveness of, and Monitor for Hepatotoxicity and Resistance to, Cabotegravir for Pre-Exposure Prophylaxis in Europe","org_study_id":"221935","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Not yet recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 4","primary_compl_date":"12/30/2029 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Incident HIV diagnoses","outcome_time_frame":"Month 6, 12, 24, 36 and at end of follow-up","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Proportion of individuals receiving CAB LA PrEP with an HIV diagnosis","outcome_time_frame":"At baseline, Months 6, 12, 24, 36 and at end of follow-up","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Proportion of participants using oral PrEP to cover planned, delayed or missed CAB LA administration","outcome_time_frame":"Month 6, 12, 24, 36 and at end of follow-up","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to incident HIV diagnosis","outcome_time_frame":"Month 6, 12, 24, 36 and at end of follow-up","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Antiretroviral therapy (ART) regimen and Viral load (VL) testing among CAB PrEP users with prevalent and incident infections","outcome_time_frame":"From baseline up to beyond 36 months","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Adherence to and Durability of CAB PrEP regimen","outcome_time_frame":"At Months 6, 12, 24, 36 and at end of follow-up","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Resistance to integrase strand transfer inhibitors (INSTIs) and specific mutations","outcome_time_frame":"At Months 6, 12, 24, 36 and at end of follow-up","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Frequency of drug-induced liver injury and hypersensitivity reactions following CAB (Oral Lead-in) OLI and CAB LA injections","outcome_time_frame":"At Months 6, 12, 24, 36 and at end of follow-up","outcome_safety_issue":null}],"product_name":"cabotegravir","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"08/23/2024 00:00:00","study_type":"Observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"221935"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}